13F Portfolios

Tri Locum Partners LP 13F: Portfolio & Holdings

In its most recent SEC Form 13F-HR filing (as of Q1 2026), Tri Locum Partners LP (SEC CIK 0001826434) reported 17 positions with a combined market value of $0.7 billion. The New York-based hedge fund has a Healthcare sector tilt, which represents 91.8% of its exposure.

Its largest holdings are Johnson & Johnson (JNJ) at 14.2%, Intuitive Surgical INC (ISRG) at 9.9%, and Thermo Fisher Scientific INC (TMO) at 9.1%.

The largest exit was Danaher (DHR) . See the fund’s full Q1 2026 buys, sells, and portfolio changes →

Based on published SEC 13F filings, Tri Locum Partners's closest peer funds by portfolio overlap are Avidity Partners Management LP (44.7%), Avoro Capital Advisors LLC (44.3%), and Deerfield Management Company, L.P. (25.1%).

13F AUM
$0.7B
Equity Positions
17
Top-10 Concentration
81.6%
Largest Sector · 91.8%
Healthcare
Longest-Held Position · 19 qtrs
UNKNOWN
Median Holding Period
1 Qtrs

What are Tri Locum Partners’s largest 13F holdings as of Q1 2026?

Largest 13F positions disclosed by Tri Locum Partners, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.

Top 10 disclosed equity positions for Tri Locum Partners in Q1 2026 — ranked by portfolio weight; share count and market value sourced from SEC Form 13F-HR filings.
# Issuer Ticker Sector Weight Position Value Detail
1 JOHNSON & JOHNSON JNJ Healthcare 14.2% $101.3M Position History All Holders
2 INTUITIVE SURGICAL INC NEW ISRG Healthcare 9.9% $70.6M Position History All Holders
3 THERMO FISHER SCIENTIFIC INC NEW TMO Healthcare 9.1% $65.1M Position History All Holders
4 ASCENDIS PHARMA A/S SYN_04351P101 Unknown 8.2% $58.4M Position History All Holders
5 VERTEX PHARMACEUTICALS NEW VRTX Healthcare 8.1% $57.7M Position History All Holders
6 ELI LILLY & CO LLY Healthcare 8.0% $56.8M Position History All Holders
7 MADRIGAL PHARMACEUTICALS INC MDGL Healthcare 7.6% $54.1M Position History All Holders
8 DEXCOM INC DXCM Healthcare 6.2% $43.8M Position History All Holders
9 UNITED THERAPEUTICS CORP DEL UTHR Healthcare 5.9% $41.7M Position History All Holders
10 NUVALENT INC NUVL Healthcare 4.4% $31.6M Position History All Holders

View Tri Locum Partners's Q1 2026 portfolio changes and trading report →

Latest

Portfolio composition

Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.

Allocation by stock17 positions · click any tile for institutional holders
Allocation by sector2 sectors · same palette as the stock tiles

Holding period analytics

Distribution of holding periods for all 293 stocks the fund has ever held (up to selected quarter):

Which Funds Hold a Similar Portfolio to Tri Locum Partners?

Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Tri Locum Partners's positions in Q1 2026.

Funds with the most portfolio overlap with Tri Locum Partners in Q1 2026 — Ranked by overlap percentage
# Fund Shared Positions Overlap %
1 Avidity Partners Management LP 3 44.7%
2 Avoro Capital Advisors LLC 5 44.3%
3 Deerfield Management Company, L.P. 3 25.1%
4 Paulson & CO. INC. 1 23.4%
5 Octagon Capital Advisors LP 2 23.2%
6 Jones Hill Capital LP 3 21.1%
7 Rtw Investments, LP 6 19.1%
8 Eagle Health Investments LP 3 16.3%
9 Fairmount Funds Management LLC 1 15.4%
10 Paradigm Biocapital Advisors LP 2 14.8%

How Has Tri Locum Partners's AUM Changed Over Time?

Quarterly 13F-reported AUM for Tri Locum Partners, derived from aggregate reported position market values disclosed to the U.S. SEC.

Methodology & FAQ

How We Track Tri Locum Partners Holdings

Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).

  • Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
  • What is Included (Data Scope): By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
  • Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
  • How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Tri Locum Partners's 13F filing disclose about their portfolio?

A Form 13F-HR filed by Tri Locum Partners with the U.S. SEC discloses all long positions in Section 13(f) securities — U.S.-listed equities, ETFs, closed-end funds, and listed put/call options — held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface the manager’s reported portfolio weights, share counts, and quarter-over-quarter portfolio changes in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.

How do you measure conviction in Tri Locum Partners's portfolio allocations?

Conviction is measured by portfolio weight — the percentage of Tri Locum Partners’s total reported 13F market value allocated to a given position — rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings.

What is excluded from Tri Locum Partners's 13F — short positions, swaps, and derivatives?

SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives — none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Tri Locum Partners’s 13F represents the reported long book, which may differ materially from its net economic exposure.

When is Tri Locum Partners's 13F data available, and how large is the reporting lag?

Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published — managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Tri Locum Partners. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.

Who must file a Form 13F with the SEC, and does Tri Locum Partners qualify?

Under SEC Rule 13f-1, any investment manager — including hedge funds, family offices, registered investment advisers, pension funds, and university endowments — that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Tri Locum Partners meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.